23rd October 2023
Our proprietary technology offers the fastest and most cost-efficient approach to hit identification that allows for serendipity and delivers high quality hits.
PHARMA
Access a unique DEL technology that allows to add a truly novel chemical space to your DEL screening decks.
BIOTECH
Benefit from serendipity in hit ID with a breakthrough DEL technology that offers lower hit attrition and lower follow-up costs.
START-UPS & RESEARCH ORGANISATIONS
Save time and budget by screening DELs that are designed for your target proteins.
What´s new
Get ready to take hit ID in drug discovery to the next level! Serengen and Deargen have partnered up to integrate their DEL and AI platforms for a faster, more affordable and effective drug discovery.
+49 (0)231 999 50 902
+49 (0)231 999 50 902
*Required
I agree that the information I supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679.
